Welcome to our dedicated page for Precigen SEC filings (Ticker: PGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UltraCAR-T, AdenoVerse, cash runway, and clinical milestones鈥擯recigen鈥檚 SEC documents pack dense science and finance into hundreds of pages. Finding the R&D spend that fuels its gene-therapy platforms or tracing when executives sell shares can feel overwhelming. Stock Titan鈥檚 AI turns that complexity into clarity, offering Precigen SEC filings explained simply and in context.
Whether you need the latest Precigen quarterly earnings report 10-Q filing or an alert on Precigen Form 4 insider transactions real-time, our platform surfaces the data as soon as it hits EDGAR. Key features:
- AI-powered summaries that reduce a 300-page 10-K to bullet-point insights鈥�Precigen annual report 10-K simplified
- One-click access to Precigen insider trading Form 4 transactions and executive stock patterns
- Contextual flags for 8-K trial updates鈥�Precigen 8-K material events explained
- AG真人官方-time monitoring of cash burn, collaboration revenue, and segment results across filings
Use cases are practical: compare quarter-over-quarter R&D trends, track Precigen proxy statement executive compensation, or run a Precigen earnings report filing analysis before your next investment committee meeting. By understanding Precigen SEC documents with AI, investors quickly see how UltraVector manufacturing efficiency or AdenoVerse vaccine data affect valuation. No more page flipping鈥攋ust the biotech insights that matter, delivered the moment PGEN files.
Precigen, Inc. reported condensed financials for the quarter ended June 30, 2025 showing regulatory progress for its lead gene therapy and material financial strain. The FDA granted priority review to the Biologics License Application for PRGN-2012, with a PDUFA target action date of August 27, 2025; PRGN-2012 is intended to treat adults with recurrent respiratory papillomatosis and has not been approved.
Financially, the company recorded a net loss of $80,795 (amounts in thousands, i.e., $80.8 million) for the six months ended June 30, 2025 and used $35,302 of cash in operating activities in that period. As of June 30, 2025, it held $13,760 in cash and $45,993 in short-term investments (totaling $59,753). Warrant liabilities were $78,558 and Series A preferred mezzanine equity was $30,883, while accumulated deficit totaled $2,171,501. Management concluded these conditions raise substantial doubt about the company鈥檚 ability to continue as a going concern for one year absent additional funding or approval-related revenue.
Operationally, the company realigned to a single reporting segment and previously reduced its workforce by over 20% to focus resources on PRGN-2012. The company recorded a $3,907 goodwill impairment in Q2 2025 and recognized prior noncurrent asset impairments in 2024. These items, combined with large noncash warrant fair-value movements, contribute to earnings volatility despite regulatory momentum.
Precigen COO Rutul R. Shah received a significant equity award of 180,000 Restricted Stock Units (RSUs) on June 26, 2025. The RSUs represent the right to receive an equivalent number of Precigen common stock shares upon vesting.
The vesting schedule is structured as follows:
- 50% of RSUs vest on May 23, 2026
- Remaining 50% vest in equal monthly installments over the following three years
This Form 4 filing, executed by Donald P. Lehr as attorney-in-fact on Shah's behalf, indicates a long-term retention strategy for the Chief Operating Officer. The RSUs were granted at $0 cost to the executive, representing a significant potential value tied to future company performance and share price appreciation.
Donald P. Lehr, Chief Legal Officer of Precigen (PGEN), reported receiving 125,000 Restricted Stock Units (RSUs) on June 26, 2025. Each RSU represents a contingent right to receive one share of Precigen common stock.
The RSUs follow a specific vesting schedule: 50% will vest on May 23, 2026, with the remaining portion vesting in equal monthly installments over the subsequent three years. The RSUs were granted at no cost ($0) to the executive.
This equity compensation grant aligns the legal officer's interests with shareholders through long-term vesting requirements. The transaction was reported via Form 4 within the required reporting timeframe, with the filing made on June 28, 2025.
Helen Sabzevari, President, CEO, and Director of Precigen, received a significant equity award of 500,000 Restricted Stock Units (RSUs) on June 26, 2025. This represents a substantial insider grant that aligns executive interests with shareholder value.
Key details of the RSU grant:
- Each RSU converts to one share of Precigen common stock
- Vesting schedule: 50% vests on May 23, 2026, with remaining vesting in equal monthly installments over three years
- Grant price: $0 (typical for RSU awards)
- Ownership form: Direct
This Form 4 filing indicates continued commitment to executive retention and long-term performance alignment through equity-based compensation. The extended vesting schedule suggests a focus on long-term value creation and executive retention.
Precigen CFO Harry Thomasian Jr. received a significant equity award in the form of 175,000 Restricted Stock Units (RSUs) on June 26, 2025. The RSUs represent the right to receive an equivalent number of Precigen common stock shares.
The vesting schedule for these RSUs is structured as follows:
- 50% vesting on May 23, 2026 (initial cliff vesting)
- Remaining 50% vesting in equal monthly installments over the subsequent three years
This Form 4 filing, signed by Donald P. Lehr as attorney-in-fact, indicates a long-term retention strategy for the CFO position. The RSUs were granted at no cost ($0) to the executive, representing a significant equity incentive aligned with shareholder interests. The award demonstrates Precigen's commitment to executive compensation through equity-based incentives.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
